サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1402096

臨床腫瘍学次世代シーケンスの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023年～2030年、予測

Global Clinical Oncology Next Generation Sequencing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.95円
臨床腫瘍学次世代シーケンスの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2023年～2030年、予測
出版日: 2023年12月01日
発行: Value Market Research
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

臨床腫瘍学次世代シーケンス市場の世界需要は、調査期間2023年～2030年のCAGR16.25%で、2022年の4億2,160万米ドルから2030年にはほぼ14億619万米ドルの市場規模に達すると推定されます。

臨床腫瘍学次世代シーケンス（NGS）とは、腫瘍学（がんの治療とケア）分野における高度なゲノムシーケンス技術の応用を指します。患者の腫瘍DNAまたはRNAの包括的な解析を可能にし、がんの発生、進行、治療に対する反応を促進する遺伝子変化、変異、または変異を特定します。

市場力学

精度の向上、シーケンスの高速化、コストの削減を特徴とする次世代シーケンスの技術的進歩が、臨床腫瘍学での採用を後押ししています。個別化医療と精密腫瘍学へのパラダイムシフトにより、腫瘍遺伝学解析への利用が拡大し、個々の遺伝子プロファイルに基づくオーダーメイド治療戦略が促進されます。世界のがん罹患率の増加は、正確な腫瘍プロファイリングと治療決定を助けるNGSのような高度な診断ツールに対する需要を煽る。NGSはまた、新たなバイオマーカーや治療標的を特定し、臨床研究や臨床試験への組み込みを促進する、がん研究において極めて重要な役割を果たしています。ヘルスケアプロバイダーは、がんの診断、予後、治療選択のために、NGSベースの検査を日常臨床に組み込むことが増えています。支持的な規制環境と確立されたガイドラインが次世代シーケンサーアプリケーションを検証し、臨床現場における品質と信頼性を保証しています。技術プロバイダー、製薬会社、研究機関の間のパートナーシップと協力は、技術革新、製品開発、NGSベースの腫瘍学検査への幅広いアクセスを促進します。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは臨床腫瘍次世代シーケンサーの世界市場における各セグメントを包括的に評価することもできます。臨床腫瘍学次世代シーケンサー産業の成長と動向は、この研究に全体的なアプローチを提供します。

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける臨床腫瘍学次世代シーケンス市場の現在および将来の需要を強調する地域展望をカバーします。さらに、本レポートは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 臨床腫瘍学次世代シーケンサー - 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 臨床腫瘍学次世代シーケンサーの世界市場分析：技術別

  • 技術別概要
  • 実績データと予測データ
  • 技術別分析
  • 全ゲノムシーケンス
  • 全エクソームシーケンス
  • ターゲットシーケンス・リシーケンス

第6章 世界の臨床腫瘍学次世代シーケンサー市場分析：ワークフロー別

  • ワークフロー別概要
  • 実績データと予測データ
  • ワークフロー別分析
  • NGSプレシーケンス
  • NGSシーケンス
  • NGSデータ解析

第7章 世界の臨床腫瘍学次世代シーケンサー市場分析：用途別

  • 概要：用途別
  • 実績データと予測データ
  • 分析：用途別
  • スクリーニング（散発がん、遺伝性がん）
  • コンパニオン診断
  • その他の診断

第8章 臨床腫瘍学次世代シーケンサーの世界市場分析：最終用途別

  • 最終用途別概要
  • 実績データと予測データ
  • 最終用途別分析
  • 病院
  • クリニック
  • 研究所

第9章 臨床腫瘍学次世代シーケンサーの世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別売上分析
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第10章 臨床腫瘍次世代シーケンサー企業の競合情勢

  • 臨床腫瘍学次世代シーケンス市場の競合
  • パートナーシップ/提携/合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第11章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Illumina Inc.
  • Thermo Fisher Scientific
  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies
  • Myriad Genetics
  • Beijing Genomics Institute（BGI）
  • Perkin Elmer
  • Foundation Medicine
  • Pacific Bioscience
  • Oxford Nanopore Technologies Ltd.
  • Paradigm Diagnostics
  • Caris Life Sciences
  • Partek Inc.
  • Eurofins Scientific S.E.
  • Qiagen N.V.
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Technology (USD MN)
  • Whole Genome Sequencing Market Sales by Geography (USD MN)
  • Whole Exome Sequencing Market Sales by Geography (USD MN)
  • Targeted Sequencing & Resequencing Market Sales by Geography (USD MN)
  • Analysis Market by Workflow (USD MN)
  • NGS Pre-Sequencing Market Sales by Geography (USD MN)
  • NGS Sequencing Market Sales by Geography (USD MN)
  • NGS Data Analysis Market Sales by Geography (USD MN)
  • Analysis by Application (USD MN)
  • Screening (Sporadic Cancer, Inherited Cancer) Market Sales by Geography (USD MN)
  • Companion Diagnostics Market Sales by Geography (USD MN)
  • Other Diagnostics Market Sales by Geography (USD MN)
  • Analysis by End-use (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Clinics Market Sales by Geography (USD MN)
  • Laboratories Market Sales by Geography (USD MN)
  • Global Clinical Oncology Next Generation Sequencing Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Clinical Oncology Next Generation Sequencing Report
  • Market Research Process
  • Market Research Methodology
  • Global Clinical Oncology Next Generation Sequencing Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Technology
  • Market Attractiveness Analysis by Workflow
  • Market Attractiveness Analysis by Application
  • Market Attractiveness Analysis by End-use
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Technology (USD MN)
  • Whole Genome Sequencing Market Sales by Geography (USD MN)
  • Whole Exome Sequencing Market Sales by Geography (USD MN)
  • Targeted Sequencing & Resequencing Market Sales by Geography (USD MN)
  • Global Market Analysis by Workflow (USD MN)
  • NGS Pre-Sequencing Market Sales by Geography (USD MN)
  • NGS Sequencing Market Sales by Geography (USD MN)
  • NGS Data Analysis Market Sales by Geography (USD MN)
  • Global Market Analysis by Application (USD MN)
  • Screening (Sporadic Cancer, Inherited Cancer) Market Sales by Geography (USD MN)
  • Companion Diagnostics Market Sales by Geography (USD MN)
  • Other Diagnostics Market Sales by Geography (USD MN)
  • Global Market Analysis by End-use (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Clinics Market Sales by Geography (USD MN)
  • Laboratories Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112112976

The global demand for Clinical Oncology Next Generation Sequencing Market is presumed to reach the market size of nearly USD 1406.19 MN by 2030 from USD 421.6 MN in 2022 with a CAGR of 16.25% under the study period 2023 - 2030.

Clinical oncology next generation sequencing (NGS) refers to the application of advanced genomic sequencing technologies in the field of oncology (cancer care and treatment). It enables the comprehensive analysis of a patient's tumor DNA or RNA to identify genetic alterations, mutations, or variations that drive cancer development, progression, and response to treatments.

MARKET DYNAMICS

Technological advancements in next generation sequencing, marked by enhanced accuracy, faster sequencing, and reduced costs, drive its adoption in clinical oncology. The paradigm shift towards personalized medicine and precision oncology amplifies its use for analyzing tumor genetics, facilitating tailored treatment strategies based on individual genetic profiles. The escalating incidence of cancer globally fuels the demand for advanced diagnostic tools like NGS, aiding accurate tumor profiling and treatment decisions. NGS also plays a pivotal role in cancer research, identifying new biomarkers and therapeutic targets, and driving its incorporation into clinical studies and trials. Healthcare providers increasingly integrate NGS-based tests into routine clinical practice for cancer diagnosis, prognosis, and treatment selection. Supportive regulatory environments and established guidelines validate next generation sequencing applications, ensuring quality and reliability in clinical settings. Partnerships and collaborations between technology providers, pharmaceutical companies, and research institutions foster innovation, product development, and wider accessibility to NGS-based oncology tests.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of clinical oncology next generation sequencing. The growth and trends of clinical oncology next generation sequencing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the clinical oncology next generation sequencing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing

By Workflow

  • NGS Pre-Sequencing
  • NGS Sequencing
  • NGS Data Analysis

By Application

  • Screening (Sporadic Cancer, Inherited Cancer)
  • Companion Diagnostics
  • Other Diagnostics

By End-Use

  • Hospitals
  • Clinics
  • Laboratories

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Clinical Oncology Next Generation Sequencing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Clinical Oncology Next Generation Sequencing market include Illumina Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies, Myriad Genetics, Beijing Genomics Institute (BGI), Perkin Elmer, Foundation Medicine, Pacific Bioscience, Oxford Nanopore Technologies Ltd., Paradigm Diagnostics, Caris Life Sciences, Partek Inc., Eurofins Scientific S.E., Qiagen N.V. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Technology
    • 3.7.2 Market Attractiveness Analysis By Workflow
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By End-use
    • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY TECHNOLOGY

  • 5.1 Overview by Technology
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Technology
  • 5.4 Whole Genome Sequencing Historic and Forecast Sales by Regions
  • 5.5 Whole Exome Sequencing Historic and Forecast Sales by Regions
  • 5.6 Targeted Sequencing & Resequencing Historic and Forecast Sales by Regions

6 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY WORKFLOW

  • 6.1 Overview by Workflow
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Workflow
  • 6.4 NGS Pre-Sequencing Historic and Forecast Sales by Regions
  • 6.5 NGS Sequencing Historic and Forecast Sales by Regions
  • 6.6 NGS Data Analysis Historic and Forecast Sales by Regions

7 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY APPLICATION

  • 7.1 Overview by Application
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Application
  • 7.4 Screening (Sporadic Cancer, Inherited Cancer) Historic and Forecast Sales by Regions
  • 7.5 Companion Diagnostics Historic and Forecast Sales by Regions
  • 7.6 Other Diagnostics Historic and Forecast Sales by Regions

8 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY END-USE

  • 8.1 Overview by End-use
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End-use
  • 8.4 Hospitals Historic and Forecast Sales by Regions
  • 8.5 Clinics Historic and Forecast Sales by Regions
  • 8.6 Laboratories Historic and Forecast Sales by Regions

9 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. South East Asia Sales Analysis
    • 9.5.10. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING COMPANIES

  • 10.1. Clinical Oncology Next Generation Sequencing Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING INDUSTRY

  • 11.1. Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Illumina Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Thermo Fisher Scientific
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. F. Hoffmann-La Roche Ltd.
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. Agilent Technologies
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Myriad Genetics
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. Beijing Genomics Institute (BGI)
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Perkin Elmer
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Foundation Medicine
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Pacific Bioscience
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Oxford Nanopore Technologies Ltd.
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Paradigm Diagnostics
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Caris Life Sciences
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments
  • 11.15. Partek Inc.
    • 11.15.1. Company Overview
    • 11.15.2. Company Revenue
    • 11.15.3. Products
    • 11.15.4. Recent Developments
  • 11.16. Eurofins Scientific S.E.
    • 11.16.1. Company Overview
    • 11.16.2. Company Revenue
    • 11.16.3. Products
    • 11.16.4. Recent Developments
  • 11.17. Qiagen N.V.
    • 11.17.1. Company Overview
    • 11.17.2. Company Revenue
    • 11.17.3. Products
    • 11.17.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies